Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-04-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2011-06-359224PMID 22234683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.

  2013cited by this paper
• Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

  2012cited by this paper
• Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

  2011cited by this paper
• Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3

  2011cited by this paper
• How I treat essential thrombocythemia.

  2011cited by this paper
• Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2010cited by this paper
• Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.

  2010cited by this paper
• Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

  2010cited by this paper
• The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.

  2010cited by this paper
• Association of Cyclooxygenase-1–Dependent and –Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization

  2009cited by this paper
• Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

  2009cited by this paper
• Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden

  2009cited by this paper
• Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.

  2008cited by this paper
• Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase.

  2008cited by this paper
• Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

  2008cited by this paper
• Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Long-term management of thrombocytosis in essential thrombocythaemia

  2008cited by this paper
• Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

  2008cited by this paper
• Prevalence of polycythemia vera and essential thrombocythemia

  2008cited by this paper
• Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review.

  2007cited by this paper
• Platelet activation and atherothrombosis.

  2007cited by this paper
• Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin

  2007cited by this paper
• Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.

  2006cited by this paper
• Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers

  2006cited by this paper
• Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

  2005cited by this paper
• Low-dose aspirin for the prevention of atherothrombosis.

  2005cited by this paper
• Efficacy and safety of low-dose aspirin in polycythemia vera.

  2004cited by this paper
• Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis.

  2002cited by this paper
• Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets

  2002cited by this paper
• New quantitative parameters on a recently introduced automated blood cell counter--the XE 2100.

  2000cited by this paper
• Increased neutrophil respiratory burst in myeloproliferative disorders: selective enhancement of superoxide release triggered by receptor-mediated agonists and low responsiveness to in vitro cytokine stimulation.

  1997cited by this paper
• Isoprostanes: potential markers of oxidant stress in atherothrombotic disease.

  1997cited by this paper
• Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

  1997cited by this paper
• European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

  1996cited by this paper
• The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

  1995cited by this paper
• Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.

  1995cited by this paper
• Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

  1995cited by this paper
• Increased Thromboxane Biosynthesis in Essential Thrombocythemia

  1995cited by this paper
• Glycocalicin: a new assay--the normal plasma levels and its potential usefulness in selected diseases.

  1994cited by this paper
• Increased hydrogen peroxide formation in platelets of patients affected with essential thrombocythaemia (ET)

  1992cited by this paper
• Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine.

  1987cited by this paper
• Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders.

  1987cited by this paper
• Clinical pharmacology of platelet cyclooxygenase inhibition.

  1985cited by this paper
• Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay.

  1985cited by this paper
• Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase.

  1984cited by this paper
• Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

  1982cited by this paper
• Radioimmunoassay of serum thromboxane B2: a simple method of assessing pharmacologic effects on platelet function.

  1980cited by this paper
• Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.

  1980cited by this paper
• Inhibition of platelet prostaglandin synthetase by oral aspirin.

  1978cited by this paper

• Pharmacologic management of ET: established therapies and emerging agents

  2025cites this paper
• The prevalence and associated factors of aspirin resistance in JAK2V617F-mutated essential thrombocythemia and polycythemia vera.

  2025cites this paper
• Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases—Case-Based Narrative Review

  2025cites this paper
• Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera.

  2025cites this paper
• Acute Coronary Syndrome in Essential Thrombocythemia and Polycythemia Vera

  2025cites this paper
• Prevention of ischemic stroke in patients with myeloproliferative neoplasms

  2024cites this paper
• Pharmacologie des médicaments antiplaquettaires

  2024cites this paper
• Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial

  2024cites this paper
• Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease

  2024cites this paper
• Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients

  2024cites this paper
• Stability of the thromboxane B2 biomarker of low-dose aspirin pharmacodynamics in human whole blood and in long-term stored serum samples

  2024cites this paper
• Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk.

  2023cites this paper
• An atypical oral presentation of polycythemia vera

  2023cites this paper
• A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage

  2023cites this paper
• Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?

  2023cites this paper
• Incidence of Thrombosis at Different Sites During the Follow-Up Period in Essential Thrombocythemia: A Systematic Review and Meta-Analysis

  2023cites this paper
• Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review

  2023cites this paper
• Precision antiplatelet therapy

  2023cites this paper
• Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

  2023cites this paper
• Aberrant Platelet Aggregation as Initial Presentation of Essential Thrombocythemia: Failure of Entero-Coated Aspirin to Reduce Platelet Hyperactivation

  2023cites this paper
• Médicaments antiplaquettaires actuels et futurs

  2023cites this paper
• Update on Guidelines for the Prevention of Cancer-Associated Thrombosis.

  2022cites this paper
• Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study

  2022cites this paper
• Fifty years with aspirin and platelets

  2022cites this paper
• Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved

  2022cites this paper
• Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia

  2022cites this paper
• Cardiovascular Disease in Myeloproliferative Neoplasms

  2022cites this paper
• Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real‐life study

  2022cites this paper
• Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies

  2022cites this paper
• Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing

  2022cites this paper
• Factors Associated with Aspirin Resistance in Hong Kong Chinese Patients with Stable Coronary Heart Disease Using the Multiplate® Analyzer and Serum Thromboxane B2

  2022cites this paper
• Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions

  2022cites this paper
• Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen

  2022cites this paper
• Platelet thromboxane inhibition by low‐dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation

  2022cites this paper
• Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases

  2022influential citation
• Contemporary and future strategies in polycythemia vera.

  2022cites this paper
• Identification of High Platelet Reactivity Despite ADP P2Y 12 Inhibitor Treatment: Two Populations in the Vasodilator-Stimulated Phosphoprotein Assay and Variable PFA-P2Y Shapes of Curve

  2022cites this paper
• Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases

  2021cites this paper
• [Résistance à l'aspirine : l'ennemi de mon ami est mon ennemi].

  2021cites this paper
• Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia

  2021cites this paper
• Evaluation of the Role of Antiplatelet Medications in Cardiovascular Disease

  2021cites this paper
• Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera

  2021cites this paper
• Urinary 11‐dehydrothromboxane B2 aspirin efficacy testing is sensitive to perioperative inflammation in pediatric solid‐organ transplant patients

  2021cites this paper
• Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference?

  2021cites this paper
• Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?

  2021cites this paper
• Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model

  2021cites this paper
• Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas

  2021cites this paper
• Myasthenia Gravis and Myeloproliferative Neoplasms – Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review

  2021cites this paper
• Polycythemia Vera: Rapid Evidence Review.

  2021cites this paper
• Acetylsalicylic acid in essential thrombocythemia

  2021cites this paper
• Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 update on diagnosis, risk‐stratification, and management”

  2021cites this paper
• GTH 2021: ACROSS BORDERS

  2021cites this paper
• Polycythemia Vera (PV): Update on Emerging Treatment Options

  2021cites this paper
• In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method

  2021cites this paper
• Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease

  2021cites this paper
• Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives

  2021cites this paper
• Low-Risk Essential Thrombocythemia: A Comprehensive Review

  2021cites this paper
• Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism – results from clinical observation studies

  2020cites this paper
• New Perspectives on Polycythemia Vera: From Diagnosis to Therapy

  2020cites this paper
• A Young Woman with Thrombocytosis.

  2020cites this paper
• Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management

  2020cites this paper
• Platelet activation and multidrug resistance protein-4 expression in children and adolescents with different subtypes of primary thrombocythemia

  2020cites this paper
• Patients with Essential Thrombocythemia may be Poor Responders to Enteric-Coated Aspirin, but not to Plain Aspirin

  2020cites this paper
• Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis

  2020cites this paper
• An agenda for future research projects in polycythemia vera and essential thrombocythemia

  2020cites this paper
• A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.

  2020cites this paper
• Current management strategies for polycythemia vera and essential thrombocythemia.

  2020cites this paper
• How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms

  2020cites this paper
• New Perspectives on Polycythemia Vera

  2020cites this paper
• [Thrombosis and platelet dysfunction in myeloproliferative neoplasms].

  2020cites this paper
• Aspirin in ET: will twice a day keep thrombosis away?

  2020cites this paper
• Austrian recommendations for the management of essential thrombocythemia

  2020cites this paper
• Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms

  2019cites this paper
• Should the Argument About Aspirin Dosing be About Frequency Rather the Dose?

  2019cites this paper
• Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 Update on Diagnosis, Risk‐stratification, and Management”

  2019cites this paper
• Oral antiplatelet agents in cardiovascular disease.

  2019cites this paper
• Role of aspirin in primary prevention of cardiovascular disease

  2019cites this paper
• A high glucose level is associated with decreased aspirin-mediated acetylation of platelet cyclooxygenase (COX)-1 at serine 529: A pilot study.

  2019cites this paper
• Laboratory Monitoring of Antiplatelet Therapy

  2019cites this paper
• Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis

  2019cites this paper
• Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome

  2019cites this paper
• Characterization of aspirin esterase activity in health and disease: In vitro and ex vivo studies

  2019cites this paper
• Updates in the management of polycythemia vera and essential thrombocythemia

  2019cites this paper
• Measurement of Thromboxane Biosynthesis in Health and Disease

  2019influential citation
• Obesity and laboratory aspirin resistance in high‐risk pregnant women treated with low‐dose aspirin

  2019cites this paper
• Essential Thrombocythemia.

  2019cites this paper
• Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association

  2019cites this paper
• Acquired Disorders of Platelet Function

  2019cites this paper
• Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper

  2019cites this paper
• Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere.

  2018cites this paper
• Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and management

  2018cites this paper
• Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count

  2018cites this paper
• Weight-adjusted aspirin for cardiovascular prevention.

  2018cites this paper
• Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes

  2018cites this paper
• Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery

  2018cites this paper
• The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

  2018cites this paper
• Platelet characteristics in patients with essential thrombocytosis

  2018cites this paper
• Polycythemia vera treatment algorithm 2018

  2018cites this paper
• Aktualitások az essentialis thrombocythaemia diagnosztikájában és terápiájában

  2018cites this paper
• Obesity and Altered Aspirin Pharmacology

  2018cites this paper